Altered intracellular calcium fluxes in pancreatic cancer induced diabetes mellitus: Relevance of the S100A8 N-terminal peptide (NT-S100A8)

Journal of Cellular Physiology

Volumn 226, Issue 2, 2011, Pages 456-468

  Basso, Daniela ^a   Greco, Eliana ^a   Padoan, Andrea ^a   Fogar, Paola ^a   Scorzeto, Michele ^a   Fadi, Elisa ^a   Bozzato, Dania ^a   Moz, Stefania ^a   Navaglia, Filippo ^a   Zambon, Carlo Federico ^a   Seraglia, Roberta ^b   De Carlo, Eugenio ^a   Valerio, Anna ^a   Reggiani, Carlo ^a   Pedrazzoli, Sergio ^a   Plebani, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALGRANULIN A; GLUCOSE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; MATRIGEL; PROTEIN KINASE B; SMAD4 PROTEIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CANCER GROWTH; CANCER INVASION; CELL GROWTH; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EPIFLUORESCENCE MICROSCOPY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INSULIN RELEASE; INSULINOMA; NONHUMAN; OSCILLATION; PANCREAS CANCER; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SECRETORY CELL;

ANIMALS; CALCIUM; CALGRANULIN A; CELL LINE, TUMOR; DIABETES MELLITUS; HUMANS; INSULIN; ISLETS OF LANGERHANS; PANCREATIC NEOPLASMS; PEPTIDES; RATS; SIGNAL TRANSDUCTION;

EID: 78649659495     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22355     Document Type: Article

References (58)

1. Arumugam T, Simeone DM, Van Golen K, Logsdon CD. 2005. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 11: 5356-5364.
2. Bardeesy N, DePinho RA. 2002. Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909.
3. Basso D, Plebani M, Fogar P, Del Favero G, Briani G, Meggiato T, Panozzo MP, Ferrara C, D'Angeli F, Burlina A. 1994. Beta-cell function in pancreatic adenocarcinoma. Pancreas 9: 332-335.
4. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valerio A, Navaglia F, Zambon CF, Falda A, Pedrazzoli S, Plebani M. 2006. Pancreatic cancer-derived S-100A8 N-terminal peptide: A diabetes cause? Clin Chim Acta 372: 120-128.
5. Bode G, Lüken A, Kerkhoff C, Roth J, Ludwig S, Nacken W. 2008. Interaction between S100A8/A9 and annexin A6 is involved in the calcium-induced cell surface exposition of S100A8/A9. J Biol Chem 283: 31776-31784.
6. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. 2005a. Probability of pancreatic cancer following diabetes: A population-based study. Gastroenterology 129: 504-511.
7. Chari ST, Zapiach M, Yadav D, Rizza RA. 2005b. Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 5: 229-233.
8. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM. 2008. Pancreatic cancer-associated diabetes mellitus: Prevalence and temporal association with diagnosis of cancer. Gastroenterology 134: 95-101.
9. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. 2007. Stromal biology of pancreatic cancer. J Cell Biochem 101: 887-907.
10. Cornish CJ, Devery JM, Poronnik P, Lackmann M, Cook DI, Geczy CL. 1996. S100 protein CP-10 stimulates myeloid cell chemotaxis without activation. J Cell Physiol 166: 427-437.
11. De Carlo E, Baiguera S, Conconi MT, Vigolo S, Grandi C, Lora S, Martini C, Maffei P, Tamagno G, Vettor R, Sicolo N, Parnigotto PP. 2010. Pancreatic acellular matrix supports islet survival and function in a synthetic tubular device: In vitro and in vivo studies. Int J Mol Med 25: 195-202.
12. Donato R. 2001. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33: 637-668.
13. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, Adam D, Wajant H, Kalthoff H, Trauzold A. 2008. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68: 1443-1450.
14. Feng F, Wang L, Albanese N, Holmes A, Xia P. 2008. Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes. Endocrinology 149: 1505-1513.
15. Fogar P, Basso D, Panozzo MP, Del Favero G, Briani G, Fabris C, D'Angeli F, Meggiato T, Ferrara C, Plebani M. 1993. C-peptide pattern in patients with pancreatic cancer. Anticancer Res 13: 2577-2580.
16. Franke TF. 2008. PI3K/Akt: Getting it right matters. Oncogene 27: 6473-6488.
17. Greco E, Basso D, Fadi E, Padoan A, Fogar P, Zambon CF, Navaglia F, Bozzato D, Moz S, Pedrazzoli S, Plebani M. 2010. Analogs of vitamin E epitomized by alpha-tocopheryl succinate for pancreatic cancer treatment: In vitro results induce caution for in vivo applications. Pancreas 39: 662-668.
18. Greenlee KJ, Corry DB, Engler DA, Matsunami RK, Tessier P, Cook RG, Werb Z, Kheradmand F. 2006. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol 177: 7312-7321.
19. Grimbaldeston MA, Geczy CL, Tedla N, Finlay-Jones JJ, Hart PH. 2003. S100A8 induction in keratinocytes by ultraviolet A irradiation is dependent on reactive oxygen intermediates. J Invest Dermatol 121: 1168-1174.
20. Hayden MS, Ghosh S. 2004. Signaling to NF-kappaB. Genes Develop 18: 2195-2224.
21. He HJ, Kole S, Kwon YK, Crow MT, Bernier M. 2003. Interaction of filamin A with the insulin receptor alters insulin-dependent activation of the mitogen-activated protein kinase pathway. J Biol Chem 278: 27096-27104.
22. Hedin KE. 2002. Chemokines: New, key players in the pathobiology of pancreatic cancer. Int J Gastrointest Cancer 31: 23-29.
23. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. 2006. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 12: 1369-1375.
24. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S, Aburatani H, Maru Y. 2008. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10: 1349-1355.
25. Hitomi J, Yamaguchi K, Kikuchi Y, Kimura T, Maruyama K, Nagasaki K. 1996. A novel calcium-binding protein in amniotic fluid, CAAF1: Its molecular cloning and tissue distribution. J Cell Sci 109: 805-815.
26. Hughes K, Antonsson A, Grundstrøm T. 1998. Calmodulin dependence of NFkappaB activation. FEBS Lett 441: 132-136.
27. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. 2005. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 92: 2076-2083.
28. Isaksson B, Strömmer L, Friess H, Büchler MW, Herrington MK, Wang F, Zierath JR, Wallberg-Henriksson H, Larsson J, Permert J. 2003. Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas 26: 173-177.
29. Keleg S, Büchler P, Ludwig R, Büchler MW, Friess H. 2003. Invasion and metastasis in pancreatic cancer. Mol Cancer 2: 14.
30. Kerkhoff C, Eue I, Sorg C. 1999. The regulatory role of MRP8 (S100A8) and MRP14 (S100A9) in the transendothelial migration of human leukocytes. Pathobiology 67: 230-232.
31. Kitsou-Mylona I, Burns CJ, Squires PE, Persaud SJ, Jones PM. 2008. A role for the extracellular calcium-sensing receptor in cell-cell communication in pancreatic islets of langerhans. Cell Physiol Biochem 22: 557-566.
32. Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, Frings W, Schönlau F, Roth J, Sorg C, Nacken W. 2003. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 23: 1034-1043.
33. Maruyama Y, Ono M, Kawahara A, Yokoyama T, Basaki Y, Kage M, Aoyagi S, Kinoshita H, Kuwano M. 2006. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res 66: 6233-6242.
34. McCarty MF. 2001. Insulin secretion as a determinant of pancreatic cancer risk. Med Hypotheses 57: 146-150.
35. Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, Evans DB, Chiao PJ. 2009. Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res 7: 624-633.
36. Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR. 2008. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res 6: 1544-1553.
37. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M. 2009. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 47: 713-723.
38. Ogawa Y, Tanaka M, Inoue K, Yamaguchi K, Chijiiwa K, Mizumoto K, Tsutsu N, Nakamura Y. 2002. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 94: 2344-2349.
39. Oida Y, Yamazaki H, Tobita K, Mukai M, Ohtani Y, Miyazaki N, Abe Y, Imaizumi T, Makuuchi H, Ueyama Y, Nakamura M. 2006. Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. Oncol Rep 16: 457-463.
40. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. 2008. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134: 981-987.
41. Pannala R, Basu A, Petersen GM, Chari ST. 2009a. New-onset diabetes: A potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10: 88-95.
42. Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM, Chari ST. 2009b. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 104: 2318-2325.
43. Passey RJ, Xu K, Hume DA, Geczy CL. 1999. S100A8: Emerging functions and regulation. J Leukoc Biol 66: 549-556.
44. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. 1993. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 80: 1047-1050.
45. Rustenbeck I, Wienbergen A, Bleck C, Jörns A. 2004. Desensitization of insulin secretion by depolarizing insulin secretagogues. Diabetes 53: S140-S150.
46. Rutter GA, Tsuboi T, Ravier MA. 2006. Ca2+ microdomains and the control of insulin secretion. Cell Calcium 40: 539-551.
47. Sheikh AA, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, Campbell F, Dodson A, Prime W, Crnogorac-Jurcevic T, Lemoine NR, Costello E. 2007. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics 7: 1929-1940.
48. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. 2004. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64: 9018-9026.
49. Sipos B, Möser S, Kalthoff H, Török V, Löhr M, Klöppel G. 2003. A comprehensive characterization of pancreatic ductal carcinoma cell lines: Towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452.
50. Soderling TR. 1999. The Ca-calmodulin-dependent protein kinase cascade. Trends Biochem Sci 24: 232-236.
51. Stevens RJ, Roddam AW, Beral V. 2007. Pancreatic cancer in type 1 and young-onset diabetes: Systematic review and meta-analysis. Br J Cancer 96: 507-509.
52. Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M. 2007. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol 31: 741-751.
53. Valerio A, Basso D, Fogar P, Falconi M, Greco E, Bassi C, Seraglia R, Abu-Hilal M, Navaglia F, Zambon CF, Gallo N, Falda A, Pedrazzoli S, Plebani M. 2004. Maldi-TOF analysis of portal sera of pancreatic cancer patients: identification of diabetogenic and antidiabetogenic peptides. Clin Chim Acta 343: 119-127.
54. van Lent PL, Grevers LC, Blom AB, Arntz OJ, van de Loo FA, van der Kraan P, Abdollahi-Roodsaz S, Srikrishna G, Freeze H, Sloetjes A, Nacken W, Vogl T, Roth J, van den Berg WB. 2008. Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. Arthritis Rheum 58: 3776-3787.
55. Vimalachandran D, Greenhalf W, Thompson C, Lüttges J, Prime W, Campbell F, Dodson A, Watson R, Crnogorac-Jurcevic T, Lemoine N, Neoptolemos J, Costello E. 2005. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 65: 3218-3225.
56. Wulffraat NM, Haas PJ, Frosch M, De Kleer IM, Vogl T, Brinkman DM, Quartier P, Roth J, Kuis W. 2003. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis 62: 236-241.
57. Yen T, Harrison CA, Devery JM, Leong S, Iismaa SE, Yoshimura T, Geczy CL. 1997. Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood 90: 4812-4821.
58. Zhou D, Salnikow K, Costa M. 1998. Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Res 58: 2182-2189.